ANI Pharmaceuticals (ANIP) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

ANI Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$883.37M

Latest Revenue (Q)

$227.81M

Main Segment (Y)

Sales of rare disease pharmaceutical products

Main Geography (Y)

UNITED STATES

ANI Pharmaceuticals Revenue by Period

ANI Pharmaceuticals Revenue by Year

Date	Revenue	Change
2025-12-31	$883.37M	43.78%
2024-12-31	$614.38M	26.20%
2023-12-31	$486.82M	53.87%
2022-12-31	$316.38M	46.38%
2021-12-31	$216.14M	3.67%
2020-12-31	$208.47M	0.93%
2019-12-31	$206.55M	2.47%
2018-12-31	$201.58M	13.99%
2017-12-31	$176.84M	37.49%
2016-12-31	$128.62M	68.53%
2015-12-31	$76.32M	36.36%
2014-12-31	$55.97M	86.06%
2013-12-31	$30.08M	1207.49%
2012-12-31	$2.30M	428.71%
2011-12-31	$435.16K	-82.41%
2010-12-31	$2.47M	96.67%
2009-12-31	$1.26M	-66.73%
2008-12-31	$3.78M	666.82%
2007-12-31	$493.05K	-96.59%
2006-12-31	$14.44M	5488.76%
2005-12-31	$258.35K	231.70%
2004-12-31	$77.89K	18.92%
2003-12-31	$65.49K	-97.69%
2002-12-31	$2.83M	62.18%
2001-12-31	$1.75M	100.00%
2000-12-31	-	100.00%
1999-12-31	-	-100.00%
1998-12-31	$123.06K	-

ANI Pharmaceuticals generated $883.37M in revenue during NA 2025, up 43.78% compared to the previous quarter, and up 423.73% compared to the same period a year ago.

ANI Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2025-09-30	$227.81M	7.78%
2025-06-30	$211.37M	7.23%
2025-03-31	$197.12M	3.44%
2024-12-31	$190.57M	28.48%
2024-09-30	$148.33M	7.46%
2024-06-30	$138.04M	0.44%
2024-03-31	$137.43M	4.39%
2023-12-31	$131.65M	-0.13%
2023-09-30	$131.83M	13.11%
2023-06-30	$116.55M	9.14%
2023-03-31	$106.79M	13.32%
2022-12-31	$94.23M	12.42%
2022-09-30	$83.82M	13.49%
2022-06-30	$73.86M	14.54%
2022-03-31	$64.48M	5.82%
2021-12-31	$60.93M	17.03%
2021-09-30	$52.06M	7.07%
2021-06-30	$48.63M	-10.81%
2021-03-31	$54.52M	-4.77%
2020-12-31	$57.25M	8.07%
2020-09-30	$52.98M	9.30%
2020-06-30	$48.47M	-2.62%
2020-03-31	$49.77M	3.77%
2019-12-31	$47.97M	-6.57%
2019-09-30	$51.34M	-5.56%
2019-06-30	$54.36M	2.78%
2019-03-31	$52.89M	-7.41%
2018-12-31	$57.12M	12.66%
2018-09-30	$50.70M	7.27%
2018-06-30	$47.27M	1.69%
2018-03-31	$46.48M	-1.70%
2017-12-31	$47.29M	-1.82%
2017-09-30	$48.16M	7.60%
2017-06-30	$44.76M	22.21%
2017-03-31	$36.63M	-4.13%
2016-12-31	$38.20M	-0.83%
2016-09-30	$38.52M	22.94%
2016-06-30	$31.34M	52.45%
2016-03-31	$20.55M	13.97%
2015-12-31	$18.04M	-9.70%
2015-09-30	$19.97M	2.34%
2015-06-30	$19.52M	3.81%
2015-03-31	$18.80M	-10.64%
2014-12-31	$21.04M	20.99%
2014-09-30	$17.39M	161.58%
2014-06-30	$6.65M	-39.01%
2014-03-31	$10.90M	3.48%
2013-12-31	$10.53M	34.41%
2013-09-30	$7.84M	27.39%
2013-06-30	$6.15M	4141.27%
2013-03-31	$145.04K	-92.63%
2012-12-31	$1.97M	1682.50%
2012-09-30	$110.38K	1.47%
2012-06-30	$108.78K	-4.58%
2012-03-31	$114.00K	-0.33%
2011-12-31	$114.37K	-37.43%
2011-09-30	$182.78K	125.65%
2011-06-30	$81.00K	42.11%
2011-03-31	$57.00K	-60.15%
2010-12-31	$143.03K	178.65%
2010-09-30	$51.33K	100.00%
2010-06-30	-	-100.00%
2010-03-31	$2.28M	114.28%
2009-12-31	$1.06M	10040.78%
2009-09-30	$10.49K	-90.89%
2009-06-30	$115.16K	68.30%
2009-03-31	$68.43K	-98.10%
2008-12-31	$3.61M	4290.78%
2008-09-30	$82.21K	217.80%
2008-06-30	$25.87K	-43.27%
2008-03-31	$45.60K	-86.15%
2007-12-31	$329.21K	-

ANI Pharmaceuticals generated $227.81M in revenue during Q3 2025, up 7.78% compared to the previous quarter, and up 165.03% compared to the same period a year ago.

ANI Pharmaceuticals Revenue Breakdown

ANI Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Total Sales of Generics and Other	$399.41M	$320.03M	-	-	-
Sales of rare disease pharmaceutical products	$422.65M	$229.60M	$112.12M	$41.69M	-
Sales of Established Brands	$61.31M	$64.74M	-	-	-
Unapproved Products	-	$22.40M	-	-	-
Sales of established brand pharmaceutical products	-	-	$105.25M	$39.46M	-
Sales of generic pharmaceutical products	-	-	$269.45M	$210.12M	$143.57M
Sales of contract manufactured products	-	-	-	$4.30M	$3.80M
Royalties from licensing agreements	-	-	-	$5.37M	$11.79M
Product development services	-	-	-	$2.95M	$1.31M
Other	-	-	-	$693.00K	$1.86M
Sales of branded pharmaceutical products	-	-	-	-	$47.56M

ANI Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Sales of rare disease pharmaceutical products (47.84%), Total Sales of Generics and Other (45.21%), and Sales of Established Brands (6.94%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Sales of rare disease pharmaceutical products	$131.27M	$118.45M	$103.96M	$36.94M	$71.48M	$24.30M	$16.33M	$17.59M	$12.60M	$10.20M	$1.29M	-	-	-	-	-	-	-	-	-
Total Sales of Generics and Other	$103.47M	$98.69M	$94.21M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales of Established Brands	$12.31M	$10.68M	$13.20M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales of Generic Pharmaceutical Products	-	-	$90.30M	$98.68M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unapproved Products	-	-	-	-	$16.90M	$5.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales of generic pharmaceutical products	-	-	-	-	-	-	$70.22M	$142.42M	$63.32M	$63.71M	$58.02M	$53.14M	$49.86M	$49.11M	$41.62M	-	-	-	-	-
Sales of contract manufactured products	-	-	-	-	-	-	-	-	-	-	$4.03M	$7.50M	$7.20M	$6.20M	$2.77M	-	-	-	-	-
Royalties from licensing agreements	-	-	-	-	-	-	-	-	-	-	$1.45M	$1.82M	$194.00K	$1.90M	$585.00K	-	-	-	-	-
Product development services	-	-	-	-	-	-	-	-	-	-	$349.00K	$1.50M	$531.00K	$566.00K	$978.00K	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	-	$63.00K	$164.00K	$213.00K	$253.00K	$289.00K	-	-	-	-	-
Sales of established brand pharmaceutical products	-	-	-	-	-	-	-	-	-	-	$12.73M	$9.82M	$8.46M	$8.45M	-	-	-	-	-	-
Sales of branded pharmaceutical products	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.69M	-	-	-	-	-
Sales Of Contract Manufactured Products	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.00M	$3.60M	$6.30M	$2.19M	$7.80M
Other Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$149.00K	$969.00K	$75.00K	$265.00K	$76.00K
Product Development Services	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$77.00K	$97.00K	$158.00K	$107.00K	$289.00K
Royalties From Licensing Agreements	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$11.21M	$276.00K	$339.00K
Sales Of Branded Pharmaceutical Products	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.31M	$11.04M	$7.52M	$15.76M	$12.41M
Sales Of Generic Pharmaceutical Products	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$35.14M	$34.20M	$32.99M	$38.65M	$37.71M

ANI Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Sales of rare disease pharmaceutical products (53.13%), Total Sales of Generics and Other (41.88%), and Sales of Established Brands (4.98%).

ANI Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
UNITED STATES	$852.44M	$604.99M	$486.25M	-	-
Non-US	$30.92M	$9.39M	-	-	-
CANADA	-	-	$565.00K	-	-
Canada	-	-	-	$3.96M	$4.24M
United States	-	-	-	$312.43M	$211.89M

ANI Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (96.50%), and Non-US (3.50%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Non-US	$8.17M	$1.22M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
United States	$182.40M	$106.22M	$93.00M	$82.85M	$72.81M	$63.76M	$59.89M	$48.23M	$46.58M	$50.03M	-	-	-	-	-	-	-	-	-	-
UNITED STATES	$182.40M	$147.12M	$137.43M	$369.70M	$116.55M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CANADA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Canada	-	-	-	-	-	$565.00K	$1.23M	$970.00K	$1.04M	$717.00K	$1.04M	$1.54M	$1.39M	$1.31M	-	-	-	-	-	-
U	-	-	-	-	-	-	-	-	-	-	-	$51.10M	$47.58M	$53.33M	$56.28M	$52.09M	$46.28M	-	-	-
C	-	-	-	-	-	-	-	-	-	-	-	$961.00K	$1.04M	$1.19M	$973.00K	$885.00K	$2.19M	-	-	-

ANI Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 24: United States (48.90%), UNITED STATES (48.90%), and Non-US (2.19%).

ANI Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ANIP	ANI Pharmaceuticals	$883.37M	$227.81M
TLRY	Tilray Brands	$821.31M	$217.51M
HROW	Harrow Health	$272.30M	$71.64M
BGM	BGM Group	$25.10M	$12.56M

ANIP Revenue FAQ

What is ANI Pharmaceuticals’s yearly revenue?

ANI Pharmaceuticals's yearly revenue for 2025 was $883.37M, representing an increase of 43.78% compared to 2024. The company's yearly revenue for 2024 was $614.38M, representing an increase of 26.20% compared to 2023. ANIP's yearly revenue for 2023 was $486.82M, representing an increase of 53.87% compared to 2022.

What is ANI Pharmaceuticals’s quarterly revenue?

ANI Pharmaceuticals's quarterly revenue for Q3 2025 was $227.81M, a 7.78% increase from the previous quarter (Q2 2025), and a 53.58% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $211.37M, a 7.23% increase from the previous quarter (Q1 2025), and a 53.12% increase year-over-year (Q2 2024). ANIP's quarterly revenue for Q1 2025 was $197.12M, a 3.44% increase from the previous quarter (Q4 2024), and a 43.43% increase year-over-year (Q1 2024).

What is ANI Pharmaceuticals’s revenue growth rate?

ANI Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 81.46%, and for the last 5 years (2021-2025) was 308.71%.

What are ANI Pharmaceuticals’s revenue streams?

ANI Pharmaceuticals's revenue streams in c 25 are Total Sales of Generics and Other, Sales of rare disease pharmaceutical products, and Sales of Established Brands. Total Sales of Generics and Other generated $399.41M in revenue, accounting 45.21% of the company's total revenue, up 24.80% year-over-year. Sales of rare disease pharmaceutical products generated $422.65M in revenue, accounting 47.84% of the company's total revenue, up 84.08% year-over-year. Sales of Established Brands generated $61.31M in revenue, accounting 6.94% of the company's total revenue, down -5.31% year-over-year.

What is ANI Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of ANI Pharmaceuticals was Sales of rare disease pharmaceutical products. This segment made a revenue of $422.65M, representing 47.84% of the company's total revenue.